Efficacy of Sunitinib and Radiotherapy in Genetically Engineered Mouse Model of Soft-Tissue Sarcoma

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 4, 2009, Pages 1207-1216

  Yoon, Sam S ^a   Stangenberg, Lars ^a   Lee, Yoon Jin ^a   Rothrock, Courtney ^a   Dreyfuss, Jonathan M ^b   Baek, Kwan Hyuck ^c   Waterman, Peter R ^a   Nielsen, G Petur ^a   Weissleder, Ralph ^a   Mahmood, Umar ^a   Park, Peter J ^b   Jacks, Tyler ^d   Dodd, Rebecca D ^e   Fisher, Carolyn J ^e   Ryeom, Sandra ^c   Kirsch, David G ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiogenesis; radiotherapy; Sarcoma; sunitinib

Indexed keywords

ANGIOGENESIS; APOPTOSIS; BEFORE AND AFTER; CANCER CELLS; COMBINATION STRATEGIES; COMBINATION THERAPY; GROWTH INHIBITION; IN-VIVO; LOCAL CONTROL; MICROVESSEL DENSITY; MINIMAL EFFECTS; MOUSE MODELS; PLATELET-DERIVED GROWTH FACTOR RECEPTORS; RECEPTOR TYROSINE KINASE; SARCOMA; SOFT TISSUE SARCOMA; SUNITINIB; SYNERGISTIC EFFECT; TARGET RECEPTOR; TUMOR GROWTH; TUMOR VASCULATURE; VASCULAR ENDOTHELIAL GROWTH FACTOR;

AMINO ACIDS; BIOACTIVITY; BLOOD VESSEL PROSTHESES; BLOOD VESSELS; CELL DEATH; CELL PROLIFERATION; ENDOTHELIAL CELLS; FLUORESCENCE; GENE EXPRESSION; ONCOLOGY; PEPTIDES; PLATELETS; RADIOTHERAPY; SELF ASSEMBLY; TOMOGRAPHY;

TUMORS;

SUNITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RADIOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TRANSGENIC MOUSE; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG SCREENING ASSAYS, ANTITUMOR; INDOLES; MICE; MICE, TRANSGENIC; PYRROLES; RANDOM ALLOCATION; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SARCOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 67649566401     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.02.052     Document Type: Article

References (23)

1. Nieder C., Wiedenmann N., Andratschke N.H., Astner S.T., and Molls M. Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience. Rev Recent Clin Trials 2 (2007) 163-168
2. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
3. Faivre S., Demetri G., Sargent W., et al. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6 (2007) 734-745
4. Yoon S.S., Segal N.H., Park P.J., et al. Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res 135 (2006) 282-290
5. Cuneo K.C., Geng L., Fu A., et al. SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 71 (2008) 873-879
6. Schueneman A.J., Himmelfarb E., Geng L., et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63 (2003) 4009-4016
7. Kirsch D.G., Dinulescu D.M., Miller J.B., et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 13 (2007) 992-997
8. Montet X., Figueiredo J.L., Alencar H., et al. Tomographic fluorescence imaging of tumor vascular volume in mice. Radiology 242 (2007) 751-758
9. Detwiller K.Y., Fernando N.T., Segal N.H., et al. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res 65 (2005) 5881-5889
10. Ryeom S., Baek K.H., Rioth M.J., et al. Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell 13 (2008) 420-431
11. Kruskal W.H., and Wallis A. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47 (1952) 583-621
12. Rae F., Woods K., Sasmono T., et al. Characterisation and trophic functions of murine embryonic macrophages based upon the use of a Csf1r-EGFP transgene reporter. Dev Biol 308 (2007) 232-246
13. Wagner M., Klussmann J.P., Fangmann R., et al. Cyclin-dependent kinase-inhibitor 1 (CDKN1A) in the squamous epithelium of the oropharynx: possible implications of molecular biology and compartmentation. Anticancer Res 21 (2001) 333-345
14. Gutmann D.H., Hunter-Schaedle K., and Shannon K.M. Harnessing preclinical mouse models to inform human clinical cancer trials. J Clin Invest 116 (2006) 847-852
15. Phung T.L., Ziv K., Dabydeen D., et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10 (2006) 159-170
16. Johannessen C.M., Johnson B.W., Williams S.M., et al. TORC1 is essential for NF1-associated malignancies. Curr Biol 18 (2008) 56-62
17. O'Connor J.P., Jackson A., Parker G.J., et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96 (2007) 189-195
18. Sahani D.V., Kalva S.P., Hamberg L.M., et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: Initial observations. Radiology 234 (2005) 785-792
19. Ellegala D.B., Leong-Poi H., Carpenter J.E., et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation 108 (2003) 336-341
20. Cho K., Wang X., Nie S., et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14 (2008) 1310-1316
21. Li C., Ke S., Wu Q.P., et al. Tumor irradiation enhances the tumor-specific distribution of poly(l-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res 6 (2000) 2829-2834
22. Wachsberger P., Burd R., and Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9 (2003) 1957-1971
23. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147